Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Przeanalizowano: 2026-05-13Następna aktualizacja: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Cena
$725.17
▲ +290.95 (+40.12%)
Wartość godziwa
$1016
$737–$1308
Rekomendacja
Zdecydowanie kupuj
confidence 79/100
Potencjał wzrostu
+40.1%
upside to fair value
Margines Bezpieczeństwa
$863.70
MoS level · 15%
Kapitalizacja
$87.2B
P/E fwd 14.4
Awaryjny angielskiPL
Pokazujemy źródło angielskie podczas tłumaczenia
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.

§1 Podsumowanie wykonawcze

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Scenariusz negatywny

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Jak ta teza może się załamać

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
Sygnały wczesnego ostrzegania do monitorowania
WskaźnikBieżącyPróg wyzwalania
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Historia finansowa

Rachunek zysków i strat — ostatnich sześć okresów
PozycjaT−0T−1T−2T−3CAGR
Okres2022-03-312023-03-312024-03-312025-03-31Trend
Przychody$263.97B$276.71B$308.95B$359.05B+10.8%
Zysk brutto$13.13B$12.36B$12.83B$13.32B+0.5%
Zysk operacyjny$2.59B$4.58B$4.17B$4.82B+22.9%
Zysk netto$1.11B$3.56B$3.00B$3.30B+43.5%
EPS (rozwodniony)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
R&D
SG&A$10.54B$7.78B$8.66B$8.51B-6.9%

Wyniki jakości

OCF / Zysk netto
1.85×
>1 wskazuje wysoką jakość wyników
Bramka jakości księgowej
Fail
Bramka skorygowana o sektor
ROIC
68.7%
Zwrot z zainwestowanego kapitału
Sekcja 3

Numbers analysis

Przepływy pieniężne

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alokacja kapitału

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Subskrybenci indywidualni — od §411 kolejnych sekcji

Przeczytaj pełną analizę — 11 kolejnych sekcji.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Pełny raport dla każdego pokrytego tickera
24 miesiące archiwum rekomendacji
Briefingi watchlisty + alerty zmian rekomendacji
Eksport PDF + DOCX w dowolnym języku
Rozpocznij darmowy okres próbny
Anuluj w dowolnym momencie.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder